Risankizumab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Risankizumab and local guidelines before prescribing.
Biologic (IL-23)
Mechanism
IL-23 p19 monoclonal antibody.
Uses
Plaque psoriasis, psoriatic arthritis, Crohn disease.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Upper respiratory infection, headache, injection-site reaction.
Interactions
Live vaccines contraindicated.
Contraindications and cautions
Active TB
Monitoring
Infection, LFT in Crohn disease
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
Screen for TB and hepatitis.
More from the textbook: uses, cautions and other points
- Adalimumab / secukinumab / ustekinumab / risankizumab | Biologics for severe psoriasis; TB and hepatitis screening.
Dermatology: Skin basics, eczema and psoriasis - Ustekinumab ; risankizumab , mirikizumab , guselkumab | IL-12/23; IL-23 | Crohn's and UC; generally well tolerated; IV induction then SC maintenance
Gastroenterology: Anatomy Physiology Pharmacology - Ustekinumab , risankizumab , mirikizumab , guselkumab .
Gastroenterology: Inflammatory Bowel Disease - Ustekinumab / risankizumab / mirikizumab / guselkumab | IL-12/23 or IL-23 blockers; IV induction, then subcutaneous.
Gastroenterology: Inflammatory Bowel Disease - IL-12/23 and IL-23 inhibitors - ustekinumab, guselkumab, risankizumab, tildrakizumab.
Dermatology: Skin basics, eczema and psoriasis - IL-12/23, IL-23 | Ustekinumab, guselkumab, risankizumab | Psoriatic arthritis (not axial disease)
Rheumatology Anatomy Physiology Pharmacology - IL-12/23 and IL-23 | Ustekinumab, guselkumab, risankizumab | Psoriatic arthritis, psoriasis, IBD | Not effective for axial disease
Rheumatology: assessment, investigations and drugs - Cytokines - signalling proteins that coordinate immunity; many are now drug targets: Cytokine Main effects Blocked by TNF-α Inflammation, fever, cachexia, granuloma maintenance Infliximab, adalimumab, etanercept IL-1 Fever, inflammation - autoinflammatory diseases, gout Anakinra, canakinumab IL-6 Acute phase response (CRP), fever …
Clinical Immunology: Immune system basics and immunological investigations
Where it is discussed in the book
- Gastroenterology: Anatomy Physiology Pharmacology (1 mention)
- Gastroenterology: Inflammatory Bowel Disease (2 mentions)
- Dermatology: Skin basics, eczema and psoriasis (2 mentions)
- Rheumatology Anatomy Physiology Pharmacology (1 mention)
- Rheumatology: assessment, investigations and drugs (1 mention)
- Clinical Immunology: Immune system basics and immunological investigations (2 mentions)
- Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology (1 mention)